TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04910100
Drug: Nebivolol Ophthalmic Suspension 0.5 Percent
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop instilled into each eye twice daily
Study: NCT04910100
Drug: Timolol Ophthalmic Suspension 0.5 Percent
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop instilled into each eye twice daily
Study: NCT04910100
Drug: Timolol Ophthalmic Solution 0.5 Percent
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop instilled into each eye twice daily
Study: NCT05850611
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first intervention group includes diabetic patients with chronic foot ulcers who, despite common treatments, will be undergone oral methylene blue intervention for 4 weeks.
Study: NCT05850611
Drug: Methylene Blue and Platelet-Rich Plasma-Fibrin Glue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C will be undergone synergistic 4-week treatment with oral methylene blue and fibrin glue.
Study: NCT05978401
Drug: GLS-012+GLS-010
Normalized name: Anti-pd-1 monoclonal antibody gls-010
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
Study: NCT05978401
Drug: GLS-012+GLS-010
Normalized name: Anti-pd-1 monoclonal antibody gls-010
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
Study: NCT05978401
Drug: GLS-012+GLS-010+pemetrexed+carboplatin
Normalized name: Carboplatin
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GLS-012+GLS-010 will be given via IV infusion on Day 1 of each 21-day cycle in combination with pemetrexed and carboplatin. Combination treatment will be administered 4\~6 cycles.GLS-012+GLS-010/GLS-010 may continue until disease progression or loss of clinical benefit.
Study: NCT05978401
Drug: GLS-012+GLS-010+paclitaxel+carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GLS-012+GLS-010 will be given via IV infusion on Day 1 of each 21-day cycle in combination with paclitaxel and carboplatin. Combination treatment will be administered 4\~6 cycles.GLS-012+GLS-010/GLS-010 may continue until disease progression or loss of clinical benefit.
Study: NCT05144529
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab IV 240 mg
Study: NCT05144529
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab IV 1 mg/kg
Study: NCT05144529
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocumab 14 mg subcutaneous injection
Study: NCT06275373
Drug: Teprotumumab Injection [Tepezza]
Normalized name: teprotumumab Injection [Tepezza]
DrugBank: Teprotumumab (DB06343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IGF1 monoclonal antibody
Study: NCT04731727
Drug: Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corneal cross linking achieved by combination of Riboflavin and ultraviolet light
Study: NCT06059287
Drug: Henagliflozin
Normalized name: Henagliflozin
DrugBank: Henagliflozin (DB11939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henagliflozin 10mg qd po
Study: NCT06059287
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1000mg bid po
Study: NCT05774067
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient received normal saline 4ml/kg/hr with deflation of tourniquet
Study: NCT05774067
Drug: glypressin
Normalized name: Lypressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient receive glypressin infusion at rate 2 mcg/kg/hr.
Study: NCT06031090
Drug: Clonidine Injection
Normalized name: clonidine Injection
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous Clonidine 0.5 µg/kg diluted in 10ml normal saline 20 minutes before spinal anesthesia
Study: NCT06031090
Drug: Granisetron Injection
Normalized name: granisetron Injection
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous 1mg of granisetron diluted in 10ml normal saline 20 minutes before spinal anesthesia.
Study: NCT05211570
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection (75 mg/m²)
Study: NCT05982470
Drug: Progesterone Soft Capsule
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone soft capsules 100mg once daily (oral) for 12 months
Study: NCT05982470
Drug: Progesterone Placebo Soft Capsule
Normalized name: progesterone Oral Capsule
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone placebo soft capsules 100mg once daily (oral) for 12 months
Study: NCT05573724
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Part A, the participants will receive Itraconazole twice daily on Day 4 and once daily on Days 5-12
Study: NCT06016400
Drug: Alfacalcidol Oral Solution
Normalized name: alfacalcidol Oral Solution
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol Oral Solution 1ug a day
Study: NCT06124573
Drug: Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet
Study: NCT05948059
Drug: SHR-2106 injection or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: starting dose from 50 mg
Study: NCT05948059
Drug: SHR-2106 injection or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: starting dose from 300 mg
Study: NCT05513365
Drug: Goserelin 10.8 mg
Normalized name: goserelin 10.8 MG
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin injection (10.8 mg) once per 3 months until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
Study: NCT05513365
Drug: Bicalutamide 50 mg
Normalized name: bicalutamide 50 MG
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide tablets (50 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
Study: NCT05513365
Drug: Dutasteride 0.5 mg
Normalized name: dutasteride 0.5 MG
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dutasteride capsules (0.5 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
Study: NCT06004765
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg/d \*21 days, 28 days for 1 course
Study: NCT06004765
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75mg/m2/d\*5 days, 28 days for 1 course
Study: NCT05909072
Drug: Hyaluronic acid combined with tranexamic acid microneedling
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 ml of TXA, available as a 500 mg/5 ml ampoule, will be applied on the right side of the face after microneedeling and left to dry
Study: NCT05909072
Drug: tranexamic acid microneedling
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On the left side of face, 0.5 ml of HA 3.5% will be used 1st followed by microneedling then 1 ml of TXA will be applied
Study: NCT05729503
Drug: Lidocaine 2% Injectable Solution
Normalized name: lidocaine 2% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotton tip applicator pre-soaked with lidocaine
Study: NCT06549296
Drug: RD06-04 CART Cell Injection
Normalized name: prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
Study: NCT00034489
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00034489
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04797468
Drug: HLX23
Normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: administered IV.
Study: NCT04724759
Drug: Dexmedetomidine / Ketamine / Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics, as needed clinically. This includes administration of 5 mcg/kg/min of ketamine plus 0.5 - 1.0 µg/kg/hr of dexmedetomidine (Precedex) as a continuous infusion, started from induction to stop one hour before surgery is anticipated to end.
Study: NCT06587789
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive ribociclib (at a dose of 400mg per day for 3 weeks, followed by 1 week off, 4 weeks for 1 cycle) plus physician-selected endocrine therapy (according to standard clinical practice, TAM or AI, with or without OFS).
Study: NCT06254183
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin is a drug that is commonly used to treat neuropathic pain, epilepsy, and other neurological disorders. According to some studies, gabapentin may affect the Wnt signaling pathway.~In this study Gabapentin will be given by a dose of 1200 mg 1 hour before a laparoscopic sleeve gastrectomy(LSG) to decrease postoperative pain and opioid consumption. As acute kidney injury is a common condition following LSG , and as gabapentin has a positive effect on decreasing AKI induced in animal studies, we assess the effect of gabapentin on the AKI status following LSG
Study: NCT05955040
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care for treatment of elevated blood pressure during pregnancy
Study: NCT05955040
Drug: Labetalol
Normalized name: Labetalol
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of care for treatment of elevated blood pressure during pregnancy
Study: NCT06518551
Drug: Elotuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanized, recombinant IgG1 monoclonal antibody, 400- and 300-mg single-use vials, via intravenous (into the vein) infusion per protocol.
Study: NCT06518551
Drug: Iberdomide
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A cereblon E3 ligase modulator, 0.15mg, 0.2mg, 0.3mg, 0.45mg, 0.6, and 0.75 mg strength capsule taken orally per protocol.
Study: NCT06518551
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Synthetic adrenocortical steroid, 2 and 4 mg tablets, taken orally per standard of care.
Study: NCT05897294
Drug: Voriconazole Inhalation Powder
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dry powder inhalation of voriconazole
Study: NCT05027581
Drug: Bone marrow mesenchymal stem cells
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The bone marrow mesenchymal stem cells (BM-MSCs) in Chondrochymal® for this study was obtained from the donor recruited in Taipei Veterans General Hospital, Taiwan. Donors aged 20 to 50 and tested negative to infection of human immunodeficiency virus type 1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis C virus (HCV), Cytomegalovirus (CMV), Treponema pallidum (syphilis), human T-lymphotropic virus types I and II (HTLV-I/II), and Tuberculosis (TB) were enrolled. The eligible donor's bone marrow was aspirated from the iliac crest or femur. The collected BM-MSCs were then cultured, expanded and cryopreserved in a Good Tissue Practice (GTP)-complied laboratory. The qualified cells in cryopreservation meeting the release criteria will be thawed, mixed with lactated Ringer's solution, and transferred into a sterile syringe as the final product.
Study: NCT05027581
Drug: hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (60 mg/3 mL hyaluronic acid \[HA\])
Study: NCT05455697
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05455697
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given vincristine
Study: NCT05455697
Drug: Polatuzumab Vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT05861570
Drug: lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
Study: NCT05861570
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound guided steroid injection using 4ml of 40mg triamcinolone acetonide
Study: NCT04682288
Drug: Levofloxacin Ocular Implant
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
Study: NCT05605613
Drug: PD-1 Antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 Antibody, an investigational humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1
Study: NCT03607175
Drug: Triamcinolone-impregnated CMC foam
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: same information as included in the arm/group descriptions
Study: NCT05267769
Drug: AP707
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Preparation of Cannabis flowers (Cannabis flos)
Study: NCT05340231
Drug: Neoadjuvant Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6, Q2W
Study: NCT04352400
Drug: Nafamostat Mesilate
Normalized name: mesylate
DrugBank: Nafamostat (DB12598)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: administered intravenously as a continuous infusion
Study: NCT05357911
Drug: AB-106, digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin
Study: NCT05142046
Drug: Fluid balance
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention consists of classic and standardized anesthesia management of children undergoing cardiac surgery. All the data links to the fluid management will be extracted from the patient's chart in the intraoperative period as well as complications during the hospitalization in the postoperative period.
Study: NCT05605925
Drug: Artemether/lumefantrine
Normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tabs artemether/lumefantrine 20/120mg, twice daily for 3 days
Study: NCT05605925
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVN 600 mcg/kg/day for 3 days
Study: NCT06308406
Drug: Bevacizumab； HRS-1167
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab: injection, 100mg(4mL), intravenous infusion HRS-1167: Tablets, 25mg/tablet, oral
Study: NCT05563766
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation
Study: NCT06464692
Drug: ABBV-400
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT00423020
Drug: Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05948449
Drug: S-1, Oxaliplatin, Cadonilimab
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 cycles of neoadjuvant therapy will be administered: S-1: 40\~60mg Bid，d1\~14, q3w Oxaliplatin：130mg/m2，iv drip，d1, q3w Cadonilimab（AK104）:10mg/Kg,iv drip,d1,q3w
Study: NCT06406426
Drug: Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cadonilimab : 6mg/kg (≤375mg) d1,15 s.c. Q4W; Fruquintinib: 3mg p.o. Q.d d1-21,Q4W.; Paclitaxel-albumin: 100 mg/m2 d1,8,15 stop for one week, i.v. Q4W
Study: NCT06267300
Drug: Hyperbaric oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (2.4 ATA, 40 sessions)
Study: NCT05979038
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients in the intervention arm will take metformin 500mg three times a day
Study: NCT06482112
Drug: Efinopegdutide
Normalized name: Efinopegdutide
DrugBank: Efinopegdutide (DB15077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm
Study: NCT04314375
Drug: Low Dose Budesonide
Normalized name: budesonide Metered Dose Nasal Spray
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 milligrams once daily for ages 5 to 11 years 11 months. 6 milligrams once daily for ages 12 to 17 years.
Study: NCT04314375
Drug: High Dose Budesonide
Normalized name: budesonide Metered Dose Nasal Spray
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 milligrams once daily for ages 5 to 11 years 11 months. 9 milligrams once daily for ages 12 to 17 years.
Study: NCT04866641
Drug: T-1201 Injection 100 mg Kit
Normalized name: sipuleucel-T Injection
DrugBank: Sipuleucel-T (DB06688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-1201 Injection 100 mg Kit contains lyophilized powder with a sterile aqueous solution formulated for intravenous administration.
Study: NCT06698692
Drug: Trilaciclib Injection [Cosela]
Normalized name: trilaciclib Injection [Cosela]
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilaciclib Combined chemoradiotherapy
Study: NCT06698848
Drug: ketamin
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in this study will have been diagnosed with major depressive episode (MDE) and have not received any psychiatric treatment for at least 2 weeks (5 weeks if on fluoxetine).Patients will receive intravenous ketamine as the only study drug treatment for the 2 weeks of the study. Magnetic Resonance Imaging (MRI) will be used to measure effects of ketamine on brain structure, function and chemistry, in addition to a soft-nasal brushing procedure to obtain olfactory sensory neurons which will provide the ability to profile in vivo how neurons may react to KET treatment in depressed patients.
Study: NCT06699459
Drug: Irinotecan Liposome
Normalized name: Irinotecan liposome
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ②LV: 400mg/m2, intravenous infusion, Q2W, d1; ③5-FU: 2400 mg/m2, continuous intravenous infusion, Q2W, d1-2;
Study: NCT06490939
Drug: Efepoetin Alfa
Normalized name: Efepoetin alfa
DrugBank: Efepoetin alfa (DB19197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-intravenous administration
Study: NCT06642584
Drug: Semaglutide B
Normalized name: Semaglutide Bulk powder
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide B will be administered subcutaneously.
Study: NCT06642584
Drug: Semaglutide J
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide J will be administered as oral tablets.
Study: NCT06642584
Drug: Semaglutide L
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide L will be administered as oral tablets.
Study: NCT06642584
Drug: Semaglutide M
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide M will be administered as oral tablets.
Study: NCT06642584
Drug: Semaglutide N
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide N will be administered as oral tablets.
Study: NCT05769816
Drug: Anti-PD-1 antibody
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
Study: NCT06274203
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects within SCD as well as healthy controls, received monthly oral vitamin D3 dose, for 6 months, according to the baseline status of vitamin D as follows: sufficient (\>30 ng/mL): 100,000 IU, insufficient (20-29.9 ng/mL): 150,000 IU, and deficient (\<20 ng/mL): 200,000 IU.